Skip to main content
TipRanks
Go Ultimate75% OFF

Sera Prognostics (SERA) Stock Price & Analysis

109 Followers

SERA Stock Chart & Stats

$2.01$0.03(1.52%)
At close: 4:00 PM EST
$2$2.1$2.2Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.95 - $2.04
52-Week Range
$1.56 - $3.85
Previous Close
$1.98
Volume
N/A
Average Volume (3M)
31.23K
Market Cap
$79.94M
Enterprise Value
$65.34M
Total Cash (Recent Filing)
$44.09M
Total Debt (Recent Filing)
$3.27M
Price to Earnings (P/E)
―
Beta
1.48
Next Earnings
Mar 24, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Medicaid Reimbursement

State Medicaid coverage creates a durable reimbursement pathway for PreTRM and materially expands the reachable patient base. The newly covered lives can support repeat utilization and provide a foundation for broader payer adoption as Sera demonstrates clinical and economic value.

Commercial Momentum

Rapid growth in ordering physicians and test volume indicates that PreTRM is moving beyond development toward commercial adoption. If this momentum continues through payer activation and provider implementation, it can improve utilization, strengthen market position, and support operating leverage.

Liquidity Runway

A stated cash runway into fiscal year 2029 gives management time to expand commercialization, pursue reimbursement, and develop international opportunities without immediate financing pressure. This supports strategic continuity while the company works toward higher recurring test volumes.

Bears Say

Persistent Losses

The very small and volatile revenue base remains far below the company’s cost structure, while negative gross profit and large operating losses show that scale has not yet been achieved. Sustained losses could delay self-funded growth until reimbursement converts into meaningful volume.

Cash Burn

Sustained negative operating and free cash flow means commercialization is consuming substantial capital before the business produces internal funding. Unless revenue scales or costs decline, continued burn can reduce financial flexibility and increase reliance on future capital resources.

Slow Provider Adoption

The lengthy provider implementation cycle can postpone the conversion of coverage wins and physician interest into recurring, high-volume testing. This makes near-term revenue growth dependent on sustained field support and patient adoption while practices gradually incorporate PreTRM into routine care.

Sera Prognostics News

SERA FAQ

What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.56 and its highest was $3.85 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $79.94M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s next earnings report is estimated for Mar 24, 2027 (not yet confirmed), which is in 128 days.
How were Sera Prognostics’s earnings last quarter?
Sera Prognostics released its earnings results on Nov 04, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.02.
Is Sera Prognostics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.16.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 38,802,080 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Sera Prognostics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of Sera Prognostics?
Hedge funds hold Sera Prognostics shares: the largest hedge-fund position in Sera Prognostics is 70,144,152 shares, and hedge funds increased their holdings by 25.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology